Stoke: 维持“买入”评级，Zorevunersen 提交 NDA，SCN1A DS 及 STK-002 取得进展 (NASDAQ:STOK)
· seekingalpha.com
Stoke Therapeutics 维持“买入”评级，zorevunersen 达到 Dravet 综合征关键里程碑，且 STK-002 取得进展；强大的现金储备可支撑至 2028 年。点击查看更多 STOK 股票详情。
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...